Current Agreements

**Dealdoc**

# Collaborative R&D agreement for I-STAR technology in infectious disease and cancer antibody discovery

Theraclone Sciences
Pfizer

Jan 19 2011

# Collaborative R&D agreement for I-STAR technology in infectious disease and cancer antibody discovery

| | |
|---|---|
| **Companies:** | Theraclone Sciences<br>Pfizer |
| **Announcement date:** | Jan 19 2011 |
| **Deal value, US$m:** | 632.0 : sum of research funding and milestone payments |



## Details

| | |
|---|---|
| **Announcement date:** | Jan 19 2011 |
| **Industry sectors:** | Bigpharma<br>Pharmaceutical<br>Biotech |
| **Therapy areas:** | Infectives<br>Oncology |
| **Technology types:** | Antibodies » Monoclonal antibodies<br>Biological compounds |
| **Deal components:** | Collaborative R&D<br>Licensing |
| **Stages of development:** | Discovery |
| **Geographic focus:** | Worldwide |

## Financials

| | |
|---|---|
| **Deal value, US$m:** | 632.0 : sum of research funding and milestone payments |
| **Milestones, US$m:** | 632.0 : discovery, development, clinical and regulatory milestones |
| **Royalty rates, %:** | n/d : royalty payments |
| **Funding, US$m:** | n/d : research funding |

## Termsheet

29 August 2012

Theraclone Sciences announced that Pfizer has selected a third target under its multi-year research and development collaboration with Theraclone.

The collaboration, which began in January 2011, uses Theraclone’s I-STAR technology to discover monoclonal antibodies against up to four undisclosed targets in the areas of infectious disease and cancer.

I-STAR technology is used to screen and identify novel human antibodies to pathogenic agents and endogenous therapeutic targets.

Discovery efforts for the first and second target are successfully nearing completion.

Pfizer receives an exclusive worldwide license to the therapeutic antibodies discovered under the collaboration.

Theraclone  will receive undisclosed funding as a result of  the third target selection.

Theraclone is eligible to receive undisclosed royalties on sales of any developed products and up to $632 million in research funding and milestone payments upon the achievement of discovery, development, regulatory and commercialization milestones.

---

19 January 2011

The collaboration will use Theraclone's I-STAR technology to discover broadly protective monoclonal antibodies against up to four undisclosed targets in the areas of infectious disease and cancer.

Theraclone and Pfizer will embark on a discovery program to identify broadly reactive antibodies directed against up to two infectious disease targets and up to two cancer targets.

Pfizer will receive an exclusive worldwide license to any therapeutic antibodies discovered under the collaboration.

Theraclone is eligible to receive undisclosed royalties on sales of any developed products and up to $632 million in research funding and milestone payments upon the achievement of discovery, development, regulatory and commercialization milestones.

Pfizer will be responsible for preclinical and clinical development of the antibodies.

## Press Release

29 August 2012

Theraclone Announces Pfizer Selects Next Target in Antibody Discovery Collaboration

Exclusive Discovery Research Partnership for Selected Infectious Disease and Cancer Targets

SEATTLE, WA — August 29, 2012 — Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced that Pfizer has selected a third target under its multi-year research and development collaboration with Theraclone. The collaboration, which began in January 2011, uses Theraclone's I-STAR™ technology to discover monoclonal antibodies against up to four undisclosed targets in the areas of infectious disease and cancer. I-STAR™ technology is used to screen and identify novel human antibodies to pathogenic agents and endogenous therapeutic targets.

Discovery efforts for the first and second target are successfully nearing completion. Pfizer receives an exclusive worldwide license to the therapeutic antibodies discovered under the collaboration.

Theraclone will receive undisclosed funding as a result of the third target selection. Under the collaboration agreement, Theraclone is eligible to receive undisclosed royalties on sales of any developed products and up to $632 million in research funding and milestone payments upon the achievement of discovery, development, regulatory and commercialization milestones.

"Under the direction of our Chief Scientific Officer, Kristine Swiderek, PhD, our collaboration with Pfizer continues to demonstrate the power of I-STAR™ technology to identify unique antibodies against novel targets," commented Clifford Stocks, Chief Executive Officer of Theraclone. "Pfizer's selection of a third target increases confidence in our approach to search the human immune repertoire to isolate rare and powerful human antibodies that may be of use in the treatment of multiple diseases," said Dr. Swiderek, adding, "we look forward to identifying antibodies for this new target and others that may result from this collaboration."

ABOUT I-STAR™ TECHNOLOGY

The human immune system responds to pathogens, like viruses and bacteria, by evolving highly protective proteins, called antibodies, in real time. The immunological history of these protective responses is archived in human memory B cells, a specialized type of blood cell. The I-STAR™ platform allows comprehensive interrogation of this memory B cell archive. I-STAR™ technology is unique in its ability to rapidly test the function of tens of thousands of natural human antibodies and find those with exceptional biologic activity. The antibodies identified through this discovery process are potentially appropriate for further development as novel therapies to help patients fight existing conditions.

ABOUT THERACLONE SCIENCES

Theraclone Sciences is a Seattle-based biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and cancer. The Company's I-STAR™ technology harnesses the power of the human immune system to identify rare, naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Theraclone has established discovery partnerships with Pfizer, Zenyaku Kogyo and the International AIDS Vaccine Research Initiative. In addition, the company has two proprietary antibody programs in clinical development for pandemic and seasonal influenza and human cytomegalovirus (HCMV). www.theraclone-sciences.com.

---

19 January 2011

SEATTLE--(BUSINESS WIRE)-- Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today that they have entered into a multi-year research and development collaboration with Pfizer. The collaboration will use Theraclone's I-STAR™ technology to discover broadly protective monoclonal antibodies against up to four undisclosed targets in the areas of infectious disease and cancer. I-STAR™ technology is used to screen and identify novel human antibodies to pathogenic agents and endogenous therapeutic targets and is unique in its ability to rapidly test the function of tens of thousands of natural human antibodies and find those with exceptional biologic activity.

Under the terms of the agreement, Theraclone and Pfizer will embark on a discovery program to identify broadly reactive antibodies directed against up to two infectious disease targets and up to two cancer targets. Pfizer will receive an exclusive worldwide license to any therapeutic antibodies discovered under the collaboration. Theraclone is eligible to receive undisclosed royalties on sales of any developed products and up to $632 million in research funding and milestone payments upon the achievement of discovery, development, regulatory and commercialization milestones. Pfizer will be responsible for preclinical and clinical development of the antibodies.

“The I-STAR™ platform has been designed to discover broadly reactive, potent antibodies with high specificity for valuable targets,” commented Dr. Steven Gillis, Interim Chief Executive Officer of Theraclone and Managing Director of ARCH Venture Partners. “This collaboration with Pfizer, and the recent published success of I-STAR™ to identify unique antibodies against novel targets in HIV and influenza, increase confidence in Theraclone's approach to search the human immune repertoire to isolate rare and powerful human antibodies that may be of use in the treatment of multiple diseases.” “Antibodies represent a very exciting class of biotherapeutics for Pfizer to combat infectious disease and are a proven approach to cancer treatment,” commented Jose-Carlos Gutiérrez-Ramos, Pfizer's Senior Vice President of Worldwide BioTherapeutics Research & Development. “Theraclone's platform technology represents an important advancement in fully-human therapeutic antibody discovery, which we believe has the potential to deliver a new generation of improved therapeutic antibodies more efficiently.”

ABOUT I-STAR™ TECHNOLOGY

The human immune system responds to pathogens, like viruses and bacteria, by evolving highly protective proteins, called antibodies, in real time. The immunological history of these protective responses is archived in human memory B cells, a specialized type of blood cell. The I-STAR™ platform allows comprehensive interrogation of this memory B cell archive. Theraclone's technology is unique, because it enables rapid functional screening of tens of thousands of natural human antibodies to find those with exceptional biological activities. The antibodies identified through this discovery process are appropriate for further development as novel therapies to help patients fight existing conditions.

ABOUT THERACLONE SCIENCES

Theraclone Sciences is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's I-STAR™ technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment. For additional information, please visit www.theraclone-sciences.com.

Contact:

MacDougall Biomedical Communications Jacqui Miller or Doug MacDougall 781-235-3060

## Filing Data

*Not available.*

## Contract

*Not available.*